H ematologic toxicity is a major and frequently doselimiting side effect of cancer chemotherapy, and transgenic expression of genes generating resistance to chemotherapeutic agents in hematopoietic cells may represent a strategy to circumvent this problem. Several genes that protect cells from the toxic effects of chemotherapeutic drugs have been identified and cloned, and a number of these chemotherapy resistance (CTX -R ) genes are presently evaluated for use in hematoprotective strategies. These include the detoxifying membrane -bound pump multidrug resistance protein -1 (MDR -1 ), proteins involved in the metabolism of cytotoxic drugs or interfering with their mode of action, such as glutathione S-transferase, cytidine deaminase, aldehyde dehydrogenase, or mutant forms of dihydrofolate reductase ( DHFR ), as well as DNA repair proteins. 1 -4 Among the DNA repair proteins, O 6 -methylguanine -DNA -methyltransferase ( MGMT ) in particular has been investigated. Whereas other DNA repair pathways involve the concerted action of multiple proteins, repair by MGMT is a one-step repair mechanism, in which the damaging alkyl group at the O 6 position of guanine is transferred to a cysteine residue within the acceptor pocket of the MGMT protein. 5 In comparison with other tissues, bone marrow cells show very low and noninducible MGMT activity, 6 -8 and this probably explains the pronounced hematotoxic potential of O 6 -alkylating agents. Whereas several investigators have shown the feasibility of hematoprotection by MGMT overexpression 9 -12 following wild -type MGMT gene transfer, the increase in CTX -R on a cellular level was only moderate and selection of transduced cells in in vivo transplant models was less than optimal. 13 -15 For clinical application of this technology, however, efficient selection of transduced cells appears necessary because, to date, gene transfer into long -lived hematopoietic stem cells per se is still relatively inefficient.
Mutant forms of MGMT (ÁMGMT ) that are resistant to the MGMT inhibitor O 6 -benzylguanine ( BG ) have recently been utilized to increase the level of protection of bone marrow -derived cells. BG is a guanine analogue, which binds to the catalytic center of MGMT and causes irreversible inactivation of the protein. 16 Recently, BG has been used in phase I studies to deplete MGMT-overexpressing tumors of O 6 -alkyl repair activity and increase the susceptibility of tumor cells to O 6 -alkylating agents such as BCNU. In these studies, severe myelosuppression was defined as the doselimiting toxicity of combined BG and BCNU treatment. 17, 18 A number of BG -resistant variants of MGMT have been evaluated for their usefulness in hematoprotective strategies including the bacterial ada methyltransferase gene, or the human MGMT G156A , MGMT P140A , and MGMT P140K mutants, and these mutants have proven effective in clonogenic progenitor cells and long -term culture -initiating cells in vitro 19, 20 as well as in murine bone marrow transplantation (BMT )/gene transfer models in vivo. 21 -23 So far, the majority of studies evaluating the hematoprotective potential of MGMT gene transfer have been performed with the chloroethylnitrosourea -type drug BCNU. 1, 4 BCNU is used in the treatment of high -grade brain tumors, and therapeutic activity has also been demonstrated in small cell lung cancer, breast cancer, and lymphoma. However, severe pulmonary fibrosis has been described following BCNU therapy, in particular at high doses. 24, 25 This specific pulmonary toxicity may be linked to spontaneous decomposition of BCNU into chloroethylisocyanate in addition to the alkylating chloroethyldiazonium moiety. 26 Chloroethyl -isocyanate is an analogue of methyl -isocyanate, a well-known and potent pulmonary toxin. 27 Besides BCNU, other O 6 -alkylating agents, including the alternative chloroethylnitrosourea-type drugs ACNU and CCNU, as well as the hydrazine and triazene derivatives procarbazine, temozolomide (TMZ ), and dacarbazine are currently in clinical use. These agents have therapeutic activity in brain tumors but also in malignant melanoma ( dacarbazine and TMZ ), soft tissue sarcoma (dacarbazine ), lymphomas (procarbazine and ACNU ), or small cell lung cancer (CCNU ). In addition, in brain tumor xenograft models, lack of cross -resistance between several O 6 -alkylating agents has been reported, as well as synergistic effects between chloroethylnitrosoureas and triazenes. 28, 29 Thus, alternative O 6 -alkylating agents offer interesting alternatives to BCNU in the context of mutant MGMT gene therapy and may allow the use of this technology in a broader spectrum of malignant diseases. Therefore, in the present investigation, we compared the hematoprotective effect of MGMT P140K gene transfer during BG /BCNU combination therapy with its effect during the combined application of BG with the alternative chloroethylnitrosourea-type agent ACNU or the triazene derivative TMZ.
Materials and methods

Retroviral vector, producer cell line, and virus production
An MSCV-based vector 30 expressing both MGMT P140K and the enhanced green fluorescence protein (EGFP ), 5 0 and 3 0 , of an encephalomyocarditis virus internal ribosomal entry site ( IRES ), respectively, was utilized. This vector is suitable for transgenic expression of the MGMT P140K mutant in hematopoietic cells and allows easy monitoring of transduced cells by the EGFP marker protein. Construction of this vector as well as generation of a stable, ecotropic, GP+E86 -based producer cell line have been described. 22 The viruscontaining supernatant was harvested after overnight incubation at 328C of confluent producer cells in IMDM medium (Sigma, Deisenhofen, Germany ), supplemented with 20% fetal calf serum (FCS; Sigma ) and 100 U /mL penicillin plus 100 g /mL streptomycin ( P/ S; both from Life Technologies, Eggenstein, Germany ), filtered through a 0.45-m filter and stored at À 808C before use.
Bone marrow preparation, transduction, and transplantation
Bone marrow was harvested from femora and tibiae of 8 -to 10-week -old female C57Bl /6 mice ( Harlan, Borchen, Germany; Janvier, Le Genest St. Isle, France ) 72 hours after treatment with 150 mg /kg 5 -fluorouracil ( Medac, Wedel, Germany ) as described previously. 22, 31 After red blood cell ( RBC ) depletion with PharM Lyse 2 ( PharMingen, Heidelberg, Germany ), according to the manufacturer's instructions, cells were prestimulated for 48 hours in -modified Eagle's medium (Sigma ) containing 20% FCS, P/ S, 100 U / mL recombinant human (rh ) IL -6 (Novartis, Basel, Switzerland ), and 50 ng/ mL recombinant murine ( rm ) SCF ( PeproTech, Rocky Hill, NJ, USA ). Transduction of prestimulated bone marrow was carried out in 10 -cm nontissue culture Petri dishes (Becton Dickinson, Heidelberg, Germany ) coated with 4 g/cm 2 retronectin (BioWhittaker, Taufkirchen, Germany ), as described previously. 22, 32 Briefly, dishes were preloaded with 4 mL of viral supernatant for 30 minutes at 378C. Thereafter, 30-50Â10 6 prestimulated bone marrow cells resuspended in 8 mL of retroviral supernatant supplemented with 100 U /mL rhIL -6 and 50 ng/ mL rmSCF were added per dish. Four hours later, the supernatant was exchanged for fresh medium, again supplemented with rhIL -6 and rmSCF. The next day, transduction was repeated for another 4 hours with fresh viral supernatant. Twenty-four hours later, cells were harvested using trypsin /EDTA (Sigma) and cell dissociation buffer ( Gibco BRL Life Technologies, Karlsruhe, Germany ) and 1.5-2.0Â10 6 cells were transplanted through tail vein into lethally irradiated ( 11 Gy, split dose, minimum of 3 hours between doses, Stabilipan X -ray Machine; Siemens, Erlangen, Germany ) female C57Bl/ 6 recipients. Bone marrow cells incubated in supplemented medium (FCS, P /S, rhIL6, rmSCF) for a total of 96 hours served as a control (mock ).
Drug treatment and sample collection
Following irradiation, mice were randomly assigned to different treatment groups or nontreated control groups. To confirm hematologic reconstitution, peripheral blood samples were taken by tail vein bleeding 24 -26 days posttransplantation and peripheral blood counts were assessed by flow cytometric analysis on a veterinary blood cell counter ( ABX, Montpellier, France ). Thereafter, weekly rounds of chemotherapy were initiated. Intraperitoneal injection of 25 mg /kg O 6 -BG ( Sigma ) dissolved in 40% polyethylene glycol 400 /60% phosphate -buffered saline ( PBS; vol /vol ) was followed 1 hour later by intraperitoneal injection of ( a ) 6 mg /kg ACNU (ASTA Medica, Frankfurt, Germany )
Cancer Gene Therapy Two days before each chemotherapy application and 5 days after the last treatment, blood samples for peripheral blood count analysis were collected by tail vein bleeding. Experiments were terminated 3-5 weeks following the last chemotherapy application. At this time point, samples for peripheral blood count analysis were collected by tail vein bleeding, animals were sacrificed, and bone marrow and spleen cells were harvested for further analysis.
Secondary transplants
From some animals, secondary transplants were performed, and 2 -3Â10 6 bone marrow cells collected from primary recipients at the end of the experiment were injected through tail vein into lethally irradiated secondary recipients. After hematologic reconstitution was confirmed, animals received four weekly cycles of combined BG /ACNU chemotherapy ( doses as described above ). As with primary transplants, 2 days before each chemotherapy application and 5 days after the last treatment, samples for peripheral blood count analysis were collected by tail vein bleeding. Secondary recipients were sacrificed and analyzed for transduced cells in hematopoietic organs 4 weeks after the last dose of chemotherapy.
Peripheral blood counts and EGFP expression analysis
Peripheral blood counts for granulocytes, lymphocytes, thrombocytes, and Hb were determined on a veterinary blood cell counter ( see above). EGFP expression analysis in peripheral blood, bone marrow, and spleen cells was assessed by flow cytometric analysis on a FACScan ( Becton Dickinson ) or a Coulter Epics XL (Coulter, Hamburg, Germany ), as described previously. 33, 34 Prior to analysis, spleen and bone marrow samples were filtered through a 70-m cell strainer ( Becton Dickinson ) to remove detritus, and for all samples, RBC depletion was performed using PharM Lyse 2 . Thereafter, cells were incubated with monoclonal antibodies for 30 minutes at 48C in PBS /0.2% (wt / vol ) bovine serum albumin (BSA ), washed once in PBS / BSA, fixed for 30 minutes in 4% formaldehyde /PBS ( vol / vol ), and washed again twice in PBS /BSA before flow cytometric analysis. Lineage -specific antibodies used were: PEconjugated rat anti -Gr-1 (RB6 -8C5 ) for granulocytes, PE -conjugated rat anti -B220 ( RA3 -6B2 ) for B cells, PEconjugated Syrian hamster anti -CD3e (500A2 ) for T cells, and PerCP-conjugated rat anti -CD4 (RM4 -5 ) for Thelper cells, all purchased from PharMingen (San Diego, CA ) and used as recommended by the manufacturer.
Statistical analysis
Unless otherwise stated, all data in the text are presented as mean ± SEM. Statistical analysis was performed by alternate t test, and P values < .05 were considered significant.
Results
Protection of the hematopoietic system from chemotherapy -induced toxicity
Hematoprotection conferred by MGMT P140K transduction of hematopoietic stem cells was assessed in a murine BMT model, in which animals transplanted with MGMT P140K -transduced bone marrow cells were repetitively challenged ( once per week, 5Â ) with the combined application of BG and the O 6 -alkylating agents ACNU, TMZ, or BCNU. Preliminary experiments established that control animals transplanted with nontransduced cells but receiving combined BG /ACNU ( seven animals ), BG / TMZ ( seven animals ), or BG /BCNU (six animals ) chemotherapy all died between weeks 4 and 5 of therapy due to progressive myelosuppression ( Fig 1a, c, e, g ). In contrast, animals transplanted with MGMT P140K -transduced cells were significantly protected from chemotherapy -induced toxicity, and 12 of 15 animals treated with BG /ACNU, all 10 animals treated with BG / TMZ, as well as all 5 animals treated with BG /BCNU survived treatment. Peripheral blood counts of 
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Hematoprotection by MGMT P140K gene transfer M Jansen et al surviving animals demonstrated substantial protection from chemotherapy-induced toxicity for all lineages of the hematopoietic system. Granulocyte counts only decreased over the first 2 weeks of treatment, but then recovered even during continued therapy (Fig 1b) . One week after the last dose of chemotherapy and at the end of the experiment, normal or near-normal granulocyte counts were detected. Peripheral blood lymphocyte and thrombocyte counts followed a similar, though somewhat delayed, pattern. Nadir values for lymphocyte counts ( Fig 1d) were detected following the second (BG /ACNU ) to fourth (BG /TMZ and BG /BCNU ) chemotherapy applications and a complete recovery of counts was detected at the end of the experiment. For thrombocyte counts (Fig 1f ) , an initial decrease during the first 2-3 weeks of treatment was followed by stable or recovering numbers thereafter.
Enrichment of transduced cells in the peripheral blood
Expression of the EGFP marker gene, which in the MSCV-MGMT P140K -EGFP vector is expressed simultaneously with the MGMT P140K gene from a common mRNA, was used to identify gene -modified cells. During chemotherapy, substantial enrichment of genetically modified granulocytes and lymphocytes was detected. After hematologic recovery from transplantation, but before the start of chemotherapy, the number of transduced cells in the peripheral blood of animals was relatively low. In the different treatment subgroups, percentage of EGFP-expressing granulocytes ranged from 1.4% to 8.6% and percentage of EGFP -expressing lymphocytes from 1.0% to 7.4% ( Fig 2) . In mice receiving no further chemotherapy, these numbers remained fairly stable over the next 8 weeks. In contrast, all animals treated with BG /O 6 -alkylating agents demonstrated a continuous increase in the percentage of transduced white blood cells during treatment, and after treatment, the percentage of EGFP-expressing cells remained stable at high levels. At the end of the experiment, i.e., 3 -5 weeks after cessation of treatment, the percentage of EGFP -expressing granulocytes was 85.9 ± 7.4% after BG /ACNU, 83.6± 8.5% after BG / TMZ, and 97.3 ± 1.7% after BG / BCNU treatment (Fig 2a ) , and the percentage of EGFP-expressing lymphocytes was 63.2 ± 7.3%, 76.7 ± 7.0%, and 64.0 ± 5.2% with BG / ACNU, BG /TMZ, and BG /BCNU treatment, respectively (Fig 2b ) . These data indicate a significant increase in absolute numbers of transduced peripheral blood cells and correlate to a 15.1-to 101.6-fold expansion of transduced granulocytes and a 16.0-to 55.3 -fold expansion of transduced lymphocytes ( Table 1 ) .
As in our retroviral construct, the EGFP marker gene is fused to the MGMT P140K c -DNA through an encephalomyocarditis IRES; the expressions of MGMT P140K and EGFP are directly correlated, allowing us to use EGFP expression to monitor MGMT P140K expression levels in transduced cells. Figure 3 demonstrates that selection primarily took place amongst transduced versus nontransduced cells. Before chemotherapy treatment ( day 26), only very few transduced, EGFP -expressing granulocytes are detected, whereas this percentage increased substantially after completion of selection therapy. This increase comes at the expense of nontransduced, non -EGFP -expressing cells. 
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In the spleen, transduction rates were assessed for total T cells (CD3 + ), T-helper cells (CD4 + / CD3 + ), and B cells ( B -220 + ). Here, percentages of EGFP -expressing cells observed in untreated control animals were 0.9 ± 0.2% for total T cells, 1.3 ± 0.3% for T-helper cells, and 0.7 ± 0.2% for B cells. Following the different therapy regimens, EGFP-expressing cells increased significantly (P < .0001 ) to 63 -70% for total T cells, 63 -73% for T-helper cells, and 50 -74% for B cells (Fig 4b ) .
Secondary transplants
Transduction of transplantable stem cells. To obtain evidence that selection of transduced cells occurred at the level of a reconstituting stem cell, serial transplants were performed from selected animals -from three mice each following BG /ACNU and BG /TMZ treatment and from one mouse following BG /BCNU application. Two to three secondary recipients were generated per primary recipient and the total number of secondary transplants was eight following BG /ACNU, nine following BG /TMZ, and three following BG /BCNU treatment. All animals survived the transplant procedure and, following hematologic recovery but before further treatment, all secondary recipients showed substantial numbers of transduced cells in the peripheral blood. Percentage of EGFP -positive granulocytes was 74.4 ± 11.4% after treatment of the primary recipient with BG /ACNU, 80.7 ± 3.7% after BG / TMZ, and 95.3 ± 3.7% after BG /BCNU treatment (Fig 5a ) . As granulocytes are short -lived cells, these data reflect a high percentage of genetically modified transplantable cells with myeloid potential present in the bone marrow of the primary recipients after selection with all three chemotherapy combinations. Data for lymphocytes were 10.8 ± 4.2%, 29.0 ± 5.9%, and 43.8 ± 8.5% for BG /ACNU -, BG /TMZ -, and BG / BCNU -treated primary recipients, respectively ( Fig 5b ) . These, in comparison with the granulocyte data, relatively low numbers probably reflect nontransduced longlived lymphocytes that have been transplanted from the primary recipient, as well as lymphocytes from the secondary recipients surviving the radiation. No significant differences in enrichment of transduced granulocytes or lymphocytes were detected between secondary recipients, whose donors were treated with different drug combinations.
Hematoprotection in secondary recipients. Subsequently, all secondary recipients were challenged with four weekly cycles of combined BG /ACNU chemotherapy, irrespective of the treatment of the primary recipients. Secondary recipients were substantially protected from the hematotoxicity L À 1 ; P = .04), as well as a lesser percentage of EGFPexpressing granulocytes ( 36± 14 vs 82 ± 4%; P = .034 ) and lymphocytes ( 12± 5 vs 27 ± 5%; P = .055 ). In contrast to primary recipients, no drop in peripheral blood counts during chemotherapy was detected in surviving secondary recipients, and granulocyte, lymphocyte, and thrombocyte counts in the peripheral blood remained fairly stable throughout the experiment (Fig 6 ) . This difference between primary and a ) Bone marrow 
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Enrichment of transduced cells in secondary recipients. Similar to the primary transplantation data, further enrichment of transduced cells during chemotherapy was observed for the secondary recipients in the peripheral blood (Fig 5 ) . Whereas 96 ± 1.6%, 96 ±1.2%, and 99± 0.3% of granulocytes expressed EGFP at the end of the experiment in the BG / ACNU, BG /TMZ, and BG /BCNU treatment groups, percentages of EGFP -expressing lymphocytes were 68 ± 5.4%, 85 ± 3.2%, and 77± 5.4%, respectively. These data correlated well with the percentage of transduced granulocytes and lymphocytes detected in bone marrow and spleen at the end of the experiment, which ranged between 68.5% and 95.3% ( Table 2) .
Discussion
The present study evaluates the effects of combined treatment with BG and the O 6 -alkylating agents ACNU, BCNU, or TMZ in a murine bone marrow transplant model allowing transgenic expression of the highly BG -resistant MGMT P140K mutant. Protection of the myeloid as well as the lymphoid compartment by expression of the MGMT P140K transgene is demonstrated for all three drug combinations. In addition, efficient selection of transduced cells is demonstrated in the granulocyte, T-, and B -lymphocyte series and secondary transplant experiments demonstrate that selection of transduced cells occurs at the level of tranplantable stem cells. Whereas the degree of selection in the lymphoid as well as the myeloid compartment of peripheral blood, bone marrow, and spleen is similar for all three drug combinations, the combinations of BG / ACNU were associated with lethalities in some primary recipient and also showed the highest lethality rate in secondary recipients. However, when body weight of animals was used as a generalized measure of chemotherapy-induced side effects, surviving animals from the BG /ACNU as well as the BG /TMZ treatment groups did relatively well, whereas BG /BCNU -treated animals showed considerable weigh loss (data not shown ). In view of these data, BG / TMZ appears to be a particularly promising combination for in vivo selection of MGMT P140K -transduced cells.
The antitumor effect of O 6 -alkylating agents is frequently compromised as tumors may overexpress wild -type MGMT as a mechanism of tumor chemoresistance, 35, 36 and efforts are underway to manipulate MGMT activity in tumor cells through systemic administration of the specific MGMT inhibitor BG. Treatment of tumors with BG has been shown to increase tumor sensitivity to O 6 -alkylating agents in vitro and deplete MGMT activity in primary tumors in vivo. 37, 38 In phase I safety studies evaluating the combined application of BG and the chloroethylnitrosourea BCNU, myelosuppression was identified as the dose -limiting toxicity. 17, 18 Thus, strategies protecting the hematopoietic system might circumvent this toxicity and improve the therapeutic efficacy of combined BG / O 6 -alkylating agent therapy. A number of BG -resistant forms of MGMT have been identified and evaluated for their potential to protect hematopoietic cells from the toxicity of combined BG / O 6 -alkylating agent application. This includes the bacterial ada gene, as well as a number of single amino acid mutations of the human MGMT gene, such as P140A, G156A, P140K, and the double mutant P140A /G156A. Several of these mutants have been evaluated successfully for protection of primary murine and human hematopoietic cells in vitro, 19, 20, 39 and in murine bone marrow transplantion models, protection of the lympho -hematopoietic system in vivo has been demonstrated. 23, 40 In particular, the P140K mutant, which in comparison to wild -type MGMT is characterized by a more than 1000 -fold increased resistance to BG, 41 has proven efficient in this context. 22, 42 In addition, xenograft studies in nude mice with the highly MGMT-expressing and O 6 -alkylating agent resistant SW480 human colon carcinoma cell line have demonstrated that myeloprotection by mutant MGMT gene transfer may allow dose escalation and improve antitumor efficacy of combined BG /O 6 -alkylating agent chemotherapy. 43 Studies with tumor cell lines as well as primary hematopoietic cells have demonstrated substantial protection by MGMT expression for the chloroethylating nitrosoureas ACNU, BCNU, CCNU, and HeCNU; the methylating triazene derivatives TMZ, procarbazine, and dacarbazine; as well as other methylating agents such as streptozotocin or ethylnitrosourea. In some of these studies, different levels of protection conferred by MGMT were reported for specific agents. For the chloroethylating agents, less protection from toxicity or chromosomal damage by MGMT expression has been described for BCNU in comparison to ACNU or CCNU in a model of MGMT-deficient and MGMTproficient HeLa cells. 44 Similar observations have been reported in primary hematopoietic progenitor cells following MGMT gene transfer. 45 As BCNU differs from other drugs in its ability to release free reactive isocyanate groups, which can inactivate proteins by reacting with the thiol groups of proteins, 46 it has been speculated that due to the carbamoylating activity of BCNU, MGMT becomes directly inactivated, which would explain the reduced protection levels of MGMT-overexpressing cells in comparison to other chloroethylating drugs. 44 The three agents evaluated in the present study, the chloroethylnitrosoureas ACNU and BCNU and the triazene derivative TMZ, are all lipophilic substances that can cross the blood -brain barrier and are currently used in the treatment of brain tumors. Therapeutic activity of BCNU has also been shown in small cell lung carcinoma and breast 
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Hematoprotection by MGMT P140K gene transfer M Jansen et al cancer, ACNU is currently being evaluated for the treatment of primary lymphomas of the brain, and TMZ has considerable activity in malignant melanoma. In addition, given the effectiveness of MGMT gene transfer in protecting from TMZ -induced hematotoxicity, this technology might also be used in the context of treatment with the mechanistically related drugs procarbazine and dacarbazine. Thus, the efficient hematoprotection demonstrated for the different treatment combinations in our study argues for the applicability of hematoprotection by ÁMGMT gene transfer in a considerable portion of oncological treatment protocols.
Gene transfer studies in large animals and in humans have been hampered by the low level of transduction of primitive stem cells and long -term expression of transduced cells in the peripheral blood of recipients. In most clinical studies, gene transfer efficiency was well below 1%. In vivo selection of transduced cells has been advocated as one way to circumvent this problem. Recently, two clinical studies incorporating modifications in the transduction protocol previously successfully tested in animal models 47 -49 have demonstrated gene transfer efficiency for long -lived transplantable stem cells above this threshold. 50, 51 In both these studies, the transferred transgenes, i.e., the gamma common chain of the IL -2 receptor superfamily and the drug resistance gene MDR -1, conferred a selective advantage to the transduced cells. This selective advantage is also present in the context of ÁMGMT gene transfer, and the murine bone marrow transplantion model used in our studies appears well suited to study the enrichment of ÁMGMT gene modified cells by BG / O 6 -alkylating agent chemotherapy. The model closely resembles the present state of clinical gene transfer studies, as 2 -5% of transduced peripheral blood cells detected after hematologic recovery, but before chemotherapeutic treatment, is within the range of the transduction efficiency achievable with current clinical gene therapy protocols. Therefore, the data presented here indicate that ÁMGMT gene transfer followed by combined BG / O 6 -alkylating agent application may be well suited to select for transduced cells in the context of clinical studies evaluating hematopoietic cell gene therapy.
In addition, our studies, in accordance with previous data generated with the same retroviral construct, demonstrate that the MSCV-MGMT P140K -EGFP vector allows simultaneous expression of two transgenes, ÁMGMT and EGFP, in Cancer Gene Therapy 19, 23 or the SF 52 backbone. Thus, in future studies, ÁMGMT gene therapy may be combined with the simultaneous delivery of other drug resistance genes, such as MDR -1 or mutant DHFR, to the hematopoietic system.
Presently, initial clinical studies are evaluating the safety of MGMT gene transfer in the treatment of glioblastomas and childhood brain tumors. Other tumor entities, which have been shown to be responsive to dose -intensive treatment with O 6 -alkylating agents and might be targeted by this approach, include lymphomas and breast cancer. 53, 54 Whereas experimental data from in vitro and animal models clearly support the concept of marrow protection by ÁMGMT gene transfer within chemotherapy protocols, feasibility and toxicity data from these early clinical studies will guide the design of future clinical trials aiming at hematoprotection by gene transfer of ÁMGMT or other drug resistance genes.
